Firouzeh Asadi

Firouzeh Asadi

Auto-generated profile, based on publicly available information

Firouzeh Asadi

Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2015 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
ABAnita Barzegar‐Fallah
Anita Barzegar‐Fallah
HAHouman Alimoradi
Houman Alimoradi
FAFirouzeh Asadi
Firouzeh Asadi
ADAhmad reza Dehpour
Ahmad reza Dehpour
MAMojgan Asgari
Mojgan Asgari
MSMassoumeh Shafiei
Massoumeh Shafiei

4 March 2016 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
FAFirouzeh Asadi
Firouzeh Asadi
ARAli Razmi
Ali Razmi
ADAhmad reza Dehpour
Ahmad reza Dehpour
MSMassoumeh Shafiei
Massoumeh Shafiei
Objectives: Cardiomyocyte hypertrophy is an important structural feature of diabetic cardiomyopathy. Calcineurin/nuclear factor of activated T-cell (NFAT) pathway plays a central role in the pathogenesis of cardiac hypertrophy. The purpose of this study was to investigate the effects of tropisetron, a novel calcineurin inhibitor, on high glucose (HG)-induced cardiomyocyte hypertrophy and its underlying mechanism. Methods: H9c2 myocardial cells were treated with tropisetron or cyclosporine A 1 h before exposure to HG for 48 h. Key findings: Exposure to HG resulted in enhanced cell size, protein content and atrial natriuretic peptide (ANP) protein expression. HG significantly increased Ca2+ level, calcineurin expression and nuclear translocation of NFATc4. Both tropisetron and cyclosporine A markedly prevented the hypertrophic characteristic features, calcineurin overexpression and nuclear localization of NFATc4 while intracellular Ca2+ was not affected. Conclusion: Our results showed that tropisetron may have protective effects against HG-induced cardiomyocyte hypertrophy. The mechanism responsible for this beneficial effect seems to be, at least in part, blockade of calcineurin/NFAT signalling pathway.

29 June 2012 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
HAHouman Alimoradi
Houman Alimoradi
ABAnita Barzegar-Fallah
Anita Barzegar-Fallah
GHGholamreza Hassanzadeh
Gholamreza Hassanzadeh
SMSanaz Mohammadi-Rick
Sanaz Mohammadi-Rick
FAFirouzeh Asadi
Firouzeh Asadi
ADAhmad reza Dehpour
Ahmad reza Dehpour